New four-drug cocktail shows promise for hard-to-treat multiple myeloma
NCT ID NCT01297764
First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 23 times
Summary
This early-phase study tested a combination of four drugs (carfilzomib, lenalidomide, vorinostat, and dexamethasone) in 17 people with multiple myeloma that had come back or stopped responding to at least one prior treatment. The main goals were to find a safe dose and see how well the drugs work together. The study is no longer recruiting, and results will help guide future treatment options for this blood cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Conditions
Explore the condition pages connected to this study.